| Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.Pediatr Blood Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39833645无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Results of the Latin American Pediatric Oncology Group (GALOP-2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval-Compressed Multiagent Chemotherapy.Pediatr Blood Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39838616无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Aprocitentan for Blood Pressure Reduction in Black Patients.Hypertension | PMID 39840441无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39843940无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431).Qual Life Res | PMID 39847268无 PMCID | 2025-Apr | 0.85 | The report is a psychometric analysis of a patient-reported outcome measure (NSCLC-SAQ) from a Phase 3 randomized trial in NSCLC. While it is an original result from a human oncology randomized trial, it does not meet the core eligibility criteria: it lacks a drug-containing intervention as the subject of the analysis and, most critically, does not report on a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The study's focus is on establishing meaningful change thresholds for a symptom assessment questionnaire. | 待处理 |
| Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial.Antiviral Res | PMID 39892563无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.Ann Surg Oncol | PMID 39893343无 PMCID | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.CPT Pharmacometrics Syst PharmacolAI 判定该论文不进入自动 KM 提取:The record describes a pharmacokinetic and exposure-response analysis of data from a study that includes a Phase III component, but the analysis itself is not the primary report of a randomized controlled trial; it focuses on modeling and does not present the trial's primary efficacy or safety endpoints as a comparative study. | PMID 39906948PMC12001254 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.Nat Med | PMID 39910273PMC12003169 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39914443无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials.Ophthalmic Surg Lasers Imaging Retina | PMID 39918755无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.Eur Neuropsychopharmacol | PMID 39923271无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.Diabetes Obes Metab | PMID 39930546PMC11885089 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preoperative visceral fat area predicts intraoperative adverse events during lymphadenectomy in laparoscopic gastrectomy for gastric cancer: a post hoc analysis.Surg Endosc | PMID 39937241无 PMCID | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.Diabetes Obes Metab | PMID 39950245PMC11885079 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.Breast | PMID 39954568PMC11875137 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.Lancet Diabetes Endocrinol | PMID 39961315无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials.Adv Ther | PMID 39969783PMC11929679 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial.Am J Respir Crit Care Med | PMID 39977011PMC12005030 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of naloxegol on transit recovery in patients undergoing cardiac surgery: A randomized, double-blind, placebo-controlled trial.Anaesth Crit Care Pain Med | PMID 39988233无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.Atherosclerosis | PMID 39999660无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study.J Dermatol | PMID 40001318PMC11975171 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.Leukemia | PMID 40016302PMC11976258 | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS.Atherosclerosis | PMID 40020597无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.Adv Ther | PMID 40025394PMC11929688 | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Polygenic Risk Score for the Efficacy of Clopidogrel in Patients With Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the CHANCE Trial.Stroke | PMID 40052280无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.Gynecol Oncol | PMID 40056832PMC12368636 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.JAMA Neurol | PMID 40067754PMC11833655 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.J Dermatol | PMID 40071721PMC11975179 | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.Lancet Haematol | PMID 40088922无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral ADC189 for adults and adolescents with uncomplicated influenza.J Infect | PMID 40089214无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study.Drugs Aging | PMID 40089969无 PMCID | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.Gynecol Oncol | PMID 40101606PMC12009185 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.ESMO Open | PMID 40107155PMC11964637 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:森林图/亚组分析图。 | PMID 40107156PMC11964640 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 40112850无 PMCID | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.Lancet Oncol | PMID 40112851无 PMCID | 2025-Apr | 0.75 | The trial meets criteria for Phase III randomized oncology human study with a time-to-event efficacy endpoint (overall survival). However, it does not meet the criterion of a drug-containing intervention. The experimental intervention is a surgical management strategy (active surveillance) versus standard surgery, both following the same neoadjuvant chemoradiotherapy. The study does not randomize patients to a drug intervention. | 待处理 |
| Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.Lancet Neurol | PMID 40120616PMC12042767 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial.Lancet Oncol | PMID 40147459无 PMCID | 2025-Apr | 0.85 | Eligible as a Phase 3 randomized oncology trial with primary results, but excluded due to lack of a time-to-event efficacy endpoint and lack of a drug-containing intervention. | 待处理 |
| Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图。 | PMID 40165400PMC11958597 | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.Alzheimers Dement | PMID 40172303PMC11963282 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40179906无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40179907无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40179908无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.J Diabetes | PMID 40214296PMC11987204 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials.JCO Clin Cancer Inform疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40215447无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.Eur J Neurol | PMID 40241307PMC12003558 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of a Single Preventive Intravenous Dose of Ketorolac and Paracetamol on Reducing Postoperative Pain in Septorhinoplasty Patients: Double-Blind Randomized Clinical Trial.Iran J Med Sci | PMID 40255229PMC12008656 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study.Alzheimers Dement | PMID 40271888PMC12019696 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Japanese participant data from three gantenerumab trials in early Alzheimer's disease.Alzheimers Dement | PMID 40302041PMC12040720 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |